{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-260671","form_type":"8-K","ticker":"SPTX","cik":"0002042347","company_name":"Seaport Therapeutics, Inc.","filed_at":"2026-06-08T11:11:42+00:00","discovered_at":"2026-06-08T11:15:00.280422+00:00","generated_at":"2026-06-08T11:17:48.391434+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Seaport Q1 net loss $25.4M; cash $212.6M; GlyphAgo Ph1 shows liver safety; GlyphAllo Ph2b on track","bullets":["Net loss $25.4M (vs $13.1M YoY); R&D expenses $21.4M, up from $10.5M YoY.","Cash $212.6M at Q1 end; +$260M from May IPO provides runway into 2029.","GlyphAgo Phase 1 MAD data show therapeutic exposures at doses avoiding liver enzyme elevations, no liver AEs.","GlyphAllo Phase 2b BUOY-1 enrollment on track; topline data 1H 2027; driving simulation trial dosed, data 2H 2026.","Sharon Mates appointed to board; upsized IPO raised $260M gross proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-260671","json":"https://secwatch.observer/filing/0001193125-26-260671.json","markdown":"https://secwatch.observer/filing/0001193125-26-260671.md","text":"https://secwatch.observer/filing/0001193125-26-260671.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526260671/0001193125-26-260671-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526260671/sptx-20260608.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T11:17:48.391434+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"daa9900cd94e91aabb325112f6122b8c0fcf2824","claim":"Seaport Therapeutics, Inc. reported financial results for the first quarter of 2026.","evidence_excerpt":"today announced financial results for the first quarter of 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/2042347/000119312526260671/0001193125-26-260671-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter of 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}